Acromegaly is a rare and debilitating disease resulting from the overproduction
of growth hormone (GH), most often due to a pituitary tumor. Overproduction
of GH results in persistent elevation in levels of insulin-like growth factor
SOMAVERT is the first and only growth hormone receptor antagonist indicated
for the treatment of acromegaly in patients who have had an inadequate response
to surgery and/or radiation therapy and/or other medical therapies, or for whom
these therapies are not appropriate. The goal of treatment is to normalize serum
SOMAVERT selectively binds to GH receptors on all cell surfaces, where it blocks
the binding of the bodys own GH. Reducing the amount of binding of the bodys
GH results in decreased serum IGF-I levels.
SOMAVERT can be ordered by your physician through the Bridge ProgramTM, a specialty
pharmacy and reimbursement assistance program that serves patients who are prescribed
If you have been diagnosed with acromegaly or suspect that you may have acromegaly,
talk to your physician and ask if SOMAVERT is right for you.
Patients and any other persons who may administer SOMAVERT should be carefully instructed by a health care professional on how to properly reconstitute and inject the product.
Patients should be informed about the need for serial monitoring of LTs, and told to immediately discontinue therapy and contact their physician if they become jaundiced. In addition, patients should be made aware that serial IGF-I levels will need to be obtained to allow their physician to properly adjust the dose of SOMAVERT.